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Information about SARS-CoV-2 is accumulating at an 
unprecedented rate. Any hope of returning to a pre-COVID 
way of life seems to rest on the shoulders of researchers tasked 
with developing effective treatments and a vaccine. 
This has generated an expectation for science to move 
faster than ever before. Evidence of acute infection can be 
assessed in a matter of days; however, the long- term effects 
may require years before reaching the threshold for clinical 
detection. Long-term effects are also subject to more confoun-
ders. Therefore, while acute care investigators are illuminating 
immediate viral effects, those studying neurodegeneration are 
left to ponder and to speculate about the downstream effects of 
viral exposure. There is now a reemerging focus on a possible 
link between SARS-CoV-2 and neurodegenerative diseases, 
specifically Parkinson’s Disease (PD) [1]. 
Many studies across the globe have published CO-
VID-19 patient characteristics and comorbidities to help us 
understand which people are more susceptible to infection and 
who is likely to have a more severe disease course. One of the 
largest studies looked at the characteristics of 5,700 patients 
hospitalised with COVID-19 [2]. Older individuals trended 
towards poorer outcomes, which is consistent with current 
thinking. Comorbidities with the largest representation 
included cancer, cardiovascular disease, chronic respiratory 
disease, immunosuppression, and others. 
PD affects over 1% of the population over the age of 60, 
and 5% of those older than 85 [3]. Moreover, PD is the second 
most common neurodegenerative disease behind Alzheimer’s 
Disease (AD), yet neither disease was represented in this 
cohort, which had a median age of 63. Perhaps there are pro-
tective factors in these otherwise vulnerable populations that 
seem to make them disproportionately less affected. It is also 
possible that medications used to treat the symptoms of PD 
and AD are effective against SARS-CoV-2.
In our Letter to the Editors of Neurologia i Neurochirurgia 
Polska, we hypothesised that some adamantane derivatives 
used in neurodegenerative populations may play a protective 
role against SARS-CoV-2 [4]. These include amantadine, 
commonly used to treat patients with PD, and memantine, 
which is commonly used in dementing illnesses such as AD. 
Our hypothesis was largely based on evidence that similar 
medications are efficacious against other coronaviruses [5]. 
Given the newness of SARS-CoV-2, this hypothesis is un-
-tested and there were no randomised control trials at the 
time. To date, there still have been no direct trials; however, 
supportive evidence is emerging. In this issue, Cortés Borra 
responds to our Letter to the Editors, and describes a 75-year-
-old woman with a longstanding history of PD treated with 
amantadine, among other medications [6]. Unfortunately, the 
woman’s husband died from COVID-19 pneumonia. Despite 
an almost certain SARS-CoV-2 exposure from direct contact 
with her husband, COVID-19 PCR testing was negative, and 
she remained symptom-free.
Even though anecdotal evidence like this must always be 
interpreted with extreme caution, Cortés Borra’s Commentary 
appears to support our hypothesis. Adding to this is a recently 
published study that aimed at determining whether patients 
with PD were at greater risk of COVID-19 [7]. While the study 
found no significant difference from the general population, 
the authors showed that vitamin D supplementation was 
associated with lower rates of infection in patients with PD. 
We find it interesting that there was a relative risk reduction 
of 100% among PD patients on amantadine. This was not 
statistically significant, and absolute risk reduction was only 
1%; however, only 2% of PD patients were taking amantadine. 
Rejdak and Grieb found that 5/5 PD patients on amantadine 
tested positive for SARS-CoV-2 but experienced no symptoms 
after > 14 days [8]. Similarly, 7/7 patients on memantine had 
asymptomatic SARS-CoV-2 infections. 
Reports vary, but this asymptomatic rate is much higher 
than a recent report of 56% among nursing home residents whe-
re only 3% remained asymptomatic one week after testing [9]. 
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We find this difference in symptomatic rates to be remar-
kable given that elderly individuals are generally considered 
to be ‘high risk’.
It could be that the high risk of the PD population goes 
beyond that of older age, and may be tied to viral neurotro-
pism. Validating this will require well-designed studies with 
years of follow up. However, an adequately powered retro-
spective study would be sufficient to disprove our hypothesis. 
We feel this study should be conducted and, if our hypothesis 
stands, be followed by prospective validation. 
We congratulate Cortés Borra on his contribution and 
hope that others will make further progress in this field and 
thus protect our patients.
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Glossary
AD — Alzheimer’s Disease
COVID-19 — coronavirus 19
PD — Parkinson’s Disease 
SARS-CoV-2 — Severe Acute Respiratory Syndrome Coronavirus 2
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